William Oh, MD

Incidence rates for male cancers published by @pubs.acs.org. #ProstateCancer incidence spiking again? Why? Is it just an aging population? More PSA testing? Guidelines changing? @yalecancer.bsky.social

I am reposting to highlight 2 other terms we hope we can gain consensus around: ARPI (rather than ARSI, NHT etc) and Combination therapy for mHSPC (instead of doublet/triplet or treatment intensification). Please read the rationale in this short editorial. @yalecancer.bsky.social

Fascinating!

“Most study participants (44-61%) could not extract basic information—including whether they have cancer—from standard prostate cancer pathology reports but [in contrast] 93% were able to understand this diagnostic information from” patient-centered pathology reports

game-changer for tailoring treatment in high-risk cases. #Oncology #ProstateCancer @oncoalert.bsky.social
@oncbrothers.bsky.social
@apccc.bsky.social

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year active monitoring.

Precision med includes imaging to individualize care. Of 593 biopsy-naive men, 48% had (-) prostate MRIs and were followed. After 3 yrs of monitoring, clinically significant prostate cancer was detected in 4% of men with negative MRIs. Avoiding biopsies can be considered if MRI is (-)

Thanks to @yaledailynews.bsky.social for covering my journey back to Yale and @yalecancer.bsky.social to bring #precisionmedicine to the next era. yaledailynews.com/blog/2024/12...

Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer This cross-sectional study evaluates trends and factors associated with selecting active surveillance or watchful waiting among individuals with intermediate-risk prostate cancer.

How often is AS/WW used in int risk prostate cancer? Leapman et al @yalecancer.bsky.social report in JAMA that AS/WW use increased from 5 - 12.3% from 2010-20, most in GG1 dz. Treat high-risk disease early, but offer AS/WW for low + some int risk cancers. jamanetwork.com/journals/jam...

How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening? This Viewpoint explores how guideline groups can come together to agree on a framework that produces clear and unified recommendations.

#ProstateCancer screening is complicated. Unfortunately, recommendations re: screening are confusing--to the population, to those at high risk, and to physicians, as well. Can we better coordinate our guidelines among major cancer organizations?
jamanetwork.com/journals/jam...

The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development Abstract. Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clin...

⭐️Nice review @theaacr.bsky.social journal Cancer Discovery 👉🏼The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development @ptarantinomd.bsky.social

bit.ly/3YZn7OK

Vaccines against COVID-19 saved over 20 million lives in the first year alone, according to a study in Lancet Infectious Diseases. Anti vaxxers conveniently ignore such stats.

Listen.

ICYMI: *30* year outcomes from SPCG-4
dx.doi.org/10.1056/NEJM...

RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

Bluesky Is Turning Into a Strong X Alternative Bluesky has a hint of the old Twitter magic, but the feeling of freedom it offers might be even better.

“.. After an hour or so of scrolling through Bluesky the other night, I felt something I haven’t felt on social media in a long time: free.

“.. Free from Elon Musk, and his tedious quest to turn X into a right-wing echo chamber ..”

@kevinroose.com
www.nytimes.com/2024/11/22/t...

The Chemotherapy+ Foundation was founded 55 years ago to seek out new treatments for cancer patients. I am honored to Chair the Medical Advisory Council for TCF. We had our #InnovationGala at Gustavino's and awarded Roy Herbst, MD the Ezra Greenspan award, presented by Rob Winn and Katie Politi.

What’s in a Name? Why Words Matter in Advanced Prostate Cancer

Words matter in medicine: for accuracy among clinicians + researchers, and for patients, to understand their disease. We propose avoiding “castration” by unifying around HSPC and coin a new phrase ARPC for “androgen deprivation resistant prostate cancer” www.sciencedirect.com/science/arti...

I think this suggests that cancer screening will continue to rely on understanding the heterogeneity of cancer and of people. At least for now.

I am excited to join this rapidly growing #medsky community! It’s time to grow a new forum for #science-driven information and communication. #prostatecancer #precisionmedicine #medicaloncology